The specter of generic competition has long loomed around copyright’s famous drug, Sildenafil, raising questions about the outlook of similar drug holdings. While early times saw impressive profits, the exclusivity lapse has opened the path for discounted substitutes, potentially reducing profitability and presenting a genuine risk for investors